Results 201 to 210 of about 893,284 (261)

Safety and Microvascular Effect of Four-Year Aminaphtone Administration in Systemic Sclerosis Patients. [PDF]

Open Access Rheumatol
Campitiello R, Sulli A, Hysa E, Pizzorni C, Cutolo M, Paolino S, Gotelli E.   +6 more
europepmc   +1 more source

Navigating the Unknown: Scleroderma Renal Crisis and a Fatal Cardiac Complication in a Young Patient With MCTD With Coexisting Anti-U3 RNP and Anti-RNA Polymerase III Antibodies. [PDF]

Case Rep Rheumatol
Reyes-Castro T, Nabizadeh A, Nasr R, Ngo L.   +3 more
europepmc   +1 more source

Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey. [PDF]

Rheumatol Adv Pract
Lakin KS, Valenzuela A, Pauling JD, Jannat-Khah DP, Gripp K, Golam O, Domsic RT, Spiera RF, Gordon JK.   +8 more
europepmc   +1 more source

IL-17 Signaling Inhibitors in Localized Scleroderma: A Single-Center Case Series of Nine Patients. [PDF]

J Dermatol
Takahashi T, Takahashi T, Segawa Y, Oka K, Takahashi T, Asano Y.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

SYSTEMIC SCLEROSIS (SCLERODERMA)

Acta Clinica Belgica, 2007
Systemic sclerosis is a rare and often debilitating disorder characterized by a pathological triad: increased deposition of extracellular matrix and collagen in tissues, microvascular damage and dysfunction, and immune activation as evidenced by inflammation and frequent occurrence of autoantibodies.
Roufosse, Florence, Meric De Bellefon, Laurent   +1 more
openaire   +3 more sources

Localized and systemic scleroderma

Seminars in Cutaneous Medicine and Surgery, 2001
Scleroderma is a broad term encompassing both localized and systemic sclerosis. Localized scleroderma is a cutaneous limited fibrosis that manifests as plaque morphea, generalized morphea, linear scleroderma, and deep morphea. Systemic scleroderma (sclerosis) can manifest as either limited or diffuse disease.
A, Hawk, J C, English
openaire   +2 more sources

Systemic and localized scleroderma

Clinics in Dermatology, 2006
Sclerosing conditions of the skin are manifested by a full spectrum of presentations that includes skin-limited forms as well as those which can involve internal organs and result in death. At this point, we are just beginning to understand the mechanisms of tissue fibrosis, and it is likely that the fibrotic processes are a heterogeneous group of ...
Lorinda, Chung, Jan, Lin, Daniel E, Furst, David, Fiorentino   +3 more
openaire   +2 more sources

The fascia in systemic scleroderma

Journal of the American Academy of Dermatology, 1980
Diffuse fasciitis (DF) shares clinical and pathologic features with systemic (SS) and localized scleroderma. The distinct pathologic feature in DF is involvement of the deep fascia, but it is not known if these changes consistently occur in SS. In this study, ten patients with SS underwent deep biopsies for evaluation of the fascia.
M, Vázquez Botet, J L, Sánchez
openaire   +2 more sources

HLA in Systemic Scleroderma (PSS) and Familial Scleroderma

The Journal of Dermatology, 1991
AbstractHLA in systemic scleroderma (PSS), including three familial cases, is reported. Three families in which one sister developed PSS and another sister suffered from either PSS (family 1), mixed connective tissue disease (MCTD) (family 2), or Sjögren's syndrome (SjS) (family 3) were described.
T, Sasaki, K, Denpo, H, Ono, H, Nakajima
openaire   +2 more sources

Systemic Scleroderma

Medical Clinics of North America, 1989
Scleroderma encompasses a wide variety of diseases, including localized scleroderma, overlap syndromes, sclerodermoid conditions, and systemic scleroderma. This article emphasizes the systemic scleroderma.
openaire   +2 more sources